Artwork

Content provided by thescientistspeaks. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by thescientistspeaks or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Homing in on New Anticancer Targets

17:48
 
Share
 

Manage episode 303506267 series 2623015
Content provided by thescientistspeaks. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by thescientistspeaks or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Cancers are diverse and adaptable. That is why a staggering 97% of cancer drugs in clinical trials fail to receive FDA approval. Researchers try to stay one step ahead of cancer by studying the mechanisms that lead to drug resistance, finding new drug targets, and developing novel therapies, such as immunotherapeutics. In this episode narrated by Niki Spahich, Sejal Davla from The Scientist’s Creative Services team spoke with Jason Sheltzer, an assistant professor in the Department of Genomics, Genetics, and Epigenomics and Yale Cancer Center at the Yale School of Medicine, about his work on drug resistance in cancer, chromosomal instability in cancer cells, and approaches to identify new treatment strategies.

The Scientist Speaks is a podcast produced by The Scientist’s Creative Services team. Our podcast is by scientists and for scientists. Once a month, we bring you the stories behind news-worthy molecular biology research.

  continue reading

61 episodes

Artwork
iconShare
 
Manage episode 303506267 series 2623015
Content provided by thescientistspeaks. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by thescientistspeaks or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Cancers are diverse and adaptable. That is why a staggering 97% of cancer drugs in clinical trials fail to receive FDA approval. Researchers try to stay one step ahead of cancer by studying the mechanisms that lead to drug resistance, finding new drug targets, and developing novel therapies, such as immunotherapeutics. In this episode narrated by Niki Spahich, Sejal Davla from The Scientist’s Creative Services team spoke with Jason Sheltzer, an assistant professor in the Department of Genomics, Genetics, and Epigenomics and Yale Cancer Center at the Yale School of Medicine, about his work on drug resistance in cancer, chromosomal instability in cancer cells, and approaches to identify new treatment strategies.

The Scientist Speaks is a podcast produced by The Scientist’s Creative Services team. Our podcast is by scientists and for scientists. Once a month, we bring you the stories behind news-worthy molecular biology research.

  continue reading

61 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide